Systemic antifungal agents are the mainstay of treatment. Antifungal agents are used for fungicidal or fungistatic eradication of the infective organism S schenkii. [23, 24] An increase in cutaneous induration, redness, and local lymphadenopathy may be expected after treatment is started, resulting from an increased immune response to the antigenic challenge of the killed fungus. Thermal adjuvant therapy to systemic antifungals may be beneficial, as S schenckii does not survive above 39°C. [23, 24] Passive immunization with monoclonal antibody against a 70-kd putative adhesin of S schenckii induces protection in murine sporotrichosis, giving promise for future therapies for this and similar deep-space fungal infections. 
Surgery combined with antifungals for localized pulmonary disease has proven beneficial. 
Consultations may include an infectious disease specialist and/or an internist and subspecialists as indicated by organ system involvement.
What would you like to print?